Table 1.
Baseline Clinical and Pathologic Characteristics of Patients Who Underwent Liver Resection for Perihilar Cholangiocarcinoma (N = 437)
| Characteristic | Data |
|---|---|
| Age, y, median (IQR) | 66.5 (58.2–73.0) |
| Age, n (%) | |
| Younger than 65 y | 197 (45.1) |
| 65 y and older | 240 (54.9) |
| Sex, female, n (%) | 165 (37.8) |
| BMI, kg/m2, median (IQR) | 24.7 (22.2–28.2) |
| ASA 1/ASA 2, n (%) | 120 (42.6) |
| NA | 155 |
| Jaundice, present, n (%) | 284 (78.5) |
| NA | 75 |
| Ascites, n (%) | 9 (2.6) |
| NA | 84 |
| Carbohydrate antigen 19-9, U/mL, median (IQR) | 102.2 (38.0–349.2) |
| Preoperative biliary drainage/stent, performed, n (%) | 272 (75.8) |
| NA | 78 |
| Type of resection, n (%) | |
| Bile duct resection + right hepatectomy | 165 (37.7) |
| Bile duct resection + left hepatectomy | 158 (36.2) |
| Other | 114 (26.1) |
| Portal vein resection, performed, n (%) | 49 (11.2) |
| Hepatic artery resection, performed, n (%) | 15 (3.4) |
| Portal vein embolization, n (%) | 31 (7.1) |
| Estimated blood loss, mL, median (IQR) | 600 (350–1150) |
| RBC transfusion, performed, n (%) | 91 (22.9) |
| NA | 40 |
| Size, mm, median (IQR) | 25 (16–40) |
| Margin status, n (%) | |
| R0 | 296 (67.7) |
| R1 | 141 (32.3) |
| Grade, n (%) | |
| G1–G2 | 339 (77.6) |
| G3–G4 | 98 (22.4) |
| Lymph nodes examined, n, median (IQR) | 3 (1–7) |
| Metastatic nodes, median (IQR) | 0 (0–1) |
| Bismuth classification, n (%) | |
| I | 67 (15.3) |
| II | 70 (16.0) |
| IIIa/IIIb | 216 (49.5) |
| IV | 84 (19.2) |
| AJCC T stage, n (%) | |
| T1 | 49 (11.2) |
| T2a–T2b | 271 (62.0) |
| T3–T4 | 117 (26.8) |
| AJCC N stage, n (%) | |
| N0 | 208 (47.6) |
| N1 | 158 (36.2) |
| Nx | 71 (16.2) |
| Lymph node ratio, n (%) | |
| 0% | 208 (56.8) |
| 1%–25% | 57 (15.6) |
| 26%–50% | 66 (18.0) |
| >50% | 35 (9.6) |
| NA | 71 |
| Log odds of positive lymph node, n (%) | |
| Less than <2 | 100 (27.3) |
| −1.99 to −0.9 | 174 (47.5) |
| −0.89 to 1.5 | 79 (21.6) |
| >1.5 | 13 (3.6) |
| NA | 71 |
| Lymphovascular invasion, present, n (%) | 209 (47.8) |
| Perineural invasion, present, n (%) | 356 (81.5) |
| Length of stay, d, median (IQR) | 10 (7–17) |
| Patients status, death, n (%) | 309 (70.6) |
| Neoadjuvant therapy, performed, n (%) | 16 (3.9) |
| Adjuvant therapy, performed, n (%) | 110 (25.2) |
AJCC, American Joint Committee on Cancer; ASA, American Society of Anesthesiologists; IQR, interquartile range; NA, not available.